Myriad and cephalon enter into companion diagnostic agreement Full Text
Myriad Genetics,

Myriad Genetics, Inc. announced that it has signed an agreement with Cephalon Inc., a subsidiary of Teva Pharmaceutical Industries Ltd Company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase I/II clinical study. We are extremely pleased to be working with Cephalon, one of the world's leading healthcare companies, on this exciting new clinical study," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "This collaboration is a further demonstration of Myriad's commitment to and leadership in the field of companion diagnostics."

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharma News

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharma News Articles

1 FDA Releases Draft Guidance on ANDA Submissions Full Text BioPharm International, June 13, 2014    Free full text

2 The bmj does make mistakes - and big ones too Full Text Applied Clinical Trials, May 21, 2014    Free full text

3 ENTYVIO (vedolizumab) now available in the United States for the treatment of adults with UC or CD Takeda Pharmaceuticals U.S.A., June 17, 2014

4 Autoimmune diseases may succumb to new drug strategy UCSF News, May 7, 2014

5 Update on romosozumab: A humanized monoclonal antibody to sclerostin Expert Opinion on Biological Therapy, April 16, 2014    Review Article
Exclusive Author Commentary

6 Treatment for rare metabolic disease approved Full Text Drug Topics, March 3, 2014    Free full text

7 A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes British Journal of Clinical Pharmacology, February 6, 2014    Clinical Article

8 Statins in neurological disorders: An overview and update Pharmacological Research , June 26, 2014    Clinical Article

9 Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa (dabigatran etexilate) litigation Full Text Boehringer Ingelheim, May 29, 2014    Free full text

10 Validation of a patient-level medication regimen complexity index as a possible tool to identify patients for medication therapy management intervention Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, June 27, 2014    Clinical Article

11 Diabetes drug shows promise for weight loss Full Text U.S. Pharmacist, June 28, 2013    Free full text    Review Article

12 2013 new drug update: What do new approvals hold for the elderly? The Consultant Pharmacist, April 7, 2014    Review Article

13 The drug combination competition Full Text Pharmaceutical Executive Magazine, September 16, 2013    Free full text

14 Aetna weight-loss program to include Belviq, Qsymia Full Text Drug Topics, February 5, 2014    Free full text

15 Launch of the Anti-Cancer Agent "Kadcyla" Full Text Chugai Pharmaceutical Co., April 18, 2014    Free full text

16 Type 2 Diabetes: European Commission approves Jardiance (empagliflozin) Full Text Boehringer Ingelheim, May 27, 2014    Free full text

17 Generic equivalence problems come up again Full Text Applied Clinical Trials, May 21, 2014    Free full text

18 Warfarin and the new oral anticoagulants Full Text First Report Managed Care, December 3, 2013    Free full text

19 Cubist announces publication of pivotal data from SIVEXTRO (tedizolid phosphate) ESTABLISH-2 clinical trial in The Lancet Infectious Diseases Cubist Pharmaceuticals, June 11, 2014

20 Surviving the price wars in emerging markets: Three myths and three lessons Pharmaceutical Executive Magazine, June 24, 2014

Indexed Journals in Pharma News: U.S.Pharmacist, FDA Drug Alerts, Pharmiwebmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register
Upcoming Clinical Trials UPCOMING Clinical Trials

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close